Cysteine reversal of the novel neuromuscular blocking drug CW002 in dogs: Pharmacodynamics, acute cardiovascular effects, and preliminary toxicology

Anesthesiology

Volumn 112, Issue 4, 2010, Pages 900-909

  Sunaga, Hiroshi ^a   Malhotra, Jaideep K ^a   Yoon, Edward ^a   Savarese, John J ^a   Heerdt, Paul M ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; BUPRENORPHINE; CW 002; CYSTEINE; HEXAMETHONIUM; NEUROMUSCULAR BLOCKING AGENT; UNCLASSIFIED DRUG; VASOPRESSIN ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; HEART RATE; HEMODYNAMIC PARAMETERS; MALE; NEUROMUSCULAR BLOCKING; NONHUMAN; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; TOXICITY TESTING;

EID: 77950867017     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181d31f8c     Document Type: Article

References (25)

1. Belmont MR, Lien CA, Tjan J, Bradley E, Stein B, Patel SS, Savarese JJ: Clinical pharmacology of GW280430A in humans. ANESTHESIOLOGY 2004; 100:768-773 (Pubitemid 38392561)
2. Savarese JJ, Belmont MR, Hashim MA, Mook RA Jr, Boros EE, Samano V, Patel SS, Feldman PL, Schultz J-AI, McNulty M, Spitzer T, Cohn DL, Morgan P, Wastila WB: Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat: A comparison with mivacurium. ANESTHESIOLOGY 2004; 100:835-845 (Pubitemid 38392570)
3. Heerdt PM, Kang R, The A, Hashim M, Mook RJ Jr, Savarese JJ: Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs. ANESTHESIOLOGY 2004; 100:846-851 (Pubitemid 38392571)
4. Heerdt PM, Malhotra JK, Pan BY, Sunaga H, Savarese JJ: Pharmacodynamics and cardiopulmonary side effects of CW002, a cysteine-reversible neuromuscular blocking drug in dogs. ANESTHESIOLOGY 2010; 112:910-916
5. Lien CA, Savard P, Belmont M, Sunaga H, Savarese JJ: Fumarates: Unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine. J Crit Care 2009; 24:50-57
6. Naguib M, Brull SJ: Update on neuromuscular pharmacology. Curr Opin Anaesthesiol 2009; 22:483-490
7. Sigma Aldrich Material Data Safety Sheet v1.3, L-Cysteine, Product #W326305. Printed September 25, 2008. Sigma- Aldrich, Inc. 305 Spruce St., St. Louis, MO 63103
8. Miyamoto M, Murphy TH, Schnaar RL, Coyle JT: Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. J Pharmacol Exp Ther 1989; 250:1132-1140 (Pubitemid 19246731)
9. Wang X, Svedin P, Nie C, Lapatto R, Zhu C, Gustavsson M, Sandberg M, Karlsson JO, Romero R, Hagberg H, Mallard C: N-acetylcysteine reduces lipopolysaccharide-sensitized hypoxic- ischemic brain injury. Ann Neurol 2007; 61:263-271 (Pubitemid 46557350)
10. Shapre LG, Olney JW, Ohlendorf C, Lyss A, Zimmerman M, Gale B: Brain damage and associated behavioral deficits following the administration of L-cysteine to infant rats. Pharmacol Biochem Behav 1975; 3:291-298
11. Sawamoto O, Hagiwara R, Kurisu K: L-cysteine-induced brain damage in adult rats. Exp Toxicol Pathol 2004; 56: 45-52 (Pubitemid 39486845)
12. Janáky R, Varga V, Hermann A, Saransaari P, Oja SS: Mechanisms of L-cysteine neurotoxicity. Neurochem Res 2000; 25:1397-1405
13. Takemoto Y: The central effect of L-cysteine on cardiovascular system of the conscious rat. Jpn J Physiol 1995; 45:771-783 (Pubitemid 3011658)
14. Valentine CJ, Puthoff TD: Enhancing parenteral nutrition therapy for the neonate. Nutr Clin Pract 2007; 22:183-193
15. Zlotkin SH, Bryan MH, Anderson GH: Cysteine supplementation to cysteine-free intravenous feeding regimens in newborn infants. Am J Clin Nutr 1981; 34:914-923
16. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL: N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354:2773-2782 (Pubitemid 43974195)
17. Zuin R, Palamidese A, Negrin R, Catozzo L, Scarda A, Balbinot M: High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig 2005; 25:401-408 (Pubitemid 41019987)
18. Kortsalioudaki C, Taylor RM, Cheeseman P, Bansal S, Mieli- Vergani G, Dhawan A: Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Liver Transpl 2008; 14:25-30 (Pubitemid 351167985)
19. Schaller G, Pleiner J, Mittermayer F, Posch M, Kapiotis S, Wolzt M: Effects of N-acetylcysteine against systemic and renal hemodynamic effects of endotoxin in healthy humans. Crit Care Med 2007; 35:1869-1875 (Pubitemid 47220360)
20. Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, Blecha L, Lowenstein W, Martinot JL, Reynaud M, Lépine JP: New treatments for cocaine dependence: A focused review. Int J Neuropsychopharmacol 2008; 11: 425-438 (Pubitemid 351482505)
21. Ng F, Berk M, Dean O, Bush AI: Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11:851-876
22. Sandilands EA, Bateman DN: Adverse reactions associated with acetylcysteine. Clin Toxicol (Phila) 2009; 47:81-88
23. Savarese JJ, Belmont MR, Savard PR, Sunaga H, Ornum SV: The dose-response for immediate reversal of AV 002 by cysteine in the rhesus monkey. ANESTHESIOLOGY 2008; 109: A1403
24. Hallberg D, Soda M: Hepatic blood flow changes following intravenous infusion of various single amino acids in dogs. 3. Acta Chir Scand 1974; 140:388-390
25. O'Kane RL, Viña JR, Simpson I, Hawkins RA: Na-dependent neutral amino acid transporters A, ASC, and N of the blood-brain barrier: Mechanisms for neutral amino acid removal. Am J Physiol Endocrinol Metab 2004; 287:E622-9